Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability (2022 - 2024)

Sunshine Biopharma's Non-Current Deferred Tax Liability history spans 3 years, with the latest figure at -$67.0 for Q4 2024.

  • For Q4 2024, Non-Current Deferred Tax Liability changed N/A year-over-year to -$67.0; the TTM value through Dec 2024 reached -$67.0, changed N/A, while the annual FY2024 figure was -$67.0, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability reached -$67.0 in Q4 2024 per SBFM's latest filing, down from $48729.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $48729.0 in Q1 2024 to a low of -$67.0 in Q4 2024.
  • Average Non-Current Deferred Tax Liability over 3 years is $39781.0, with a median of $43032.0 recorded in 2022.
  • The largest YoY upside for Non-Current Deferred Tax Liability was 13.24% in 2024 against a maximum downside of 13.24% in 2024.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $43032.0 in 2022, then changed by 0.0% to $43032.0 in 2023, then plummeted by 100.16% to -$67.0 in 2024.
  • Per Business Quant, the three most recent readings for SBFM's Non-Current Deferred Tax Liability are -$67.0 (Q4 2024), $48729.0 (Q3 2024), and $48729.0 (Q2 2024).